---
document_datetime: 2025-12-17 23:29:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/kimmtrak.html
document_name: kimmtrak.html
version: success
processing_time: 0.1177136
conversion_datetime: 2025-12-24 05:21:42.689889
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Kimmtrak

[RSS](/en/individual-human-medicine.xml/67538)

##### Authorised

This medicine is authorised for use in the European Union

tebentafusp Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Kimmtrak](#news-on)
- [More information on Kimmtrak](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Kimmtrak is a medicine used to treat adults with a type of eye cancer called 'uveal melanoma'. It is used when the uveal melanoma cannot be removed by surgery or has spread to other parts of the body.

Uveal melanoma is rare, and Kimmtrak was designated an 'orphan medicine' (a medicine used in rare diseases) on 19 February 2021.

Expand section

Collapse section

## How is Kimmtrak used?

The medicine can only be obtained with a prescription and should be given under the supervision of a doctor experienced in the use of cancer medicines and the treatment of cytokine release syndrome (CRS - a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, headache and low blood pressure), which can occur after treatment with Kimmtrak. It should be given in a setting where CRS can be managed.

Kimmtrak is given as an infusion (drip) into a vein. The recommended dose is 20 micrograms on day 1, 30 micrograms on day 8, 68 micrograms on day 15, and 68 micrograms once every week thereafter. The patient should be hospitalised while receiving the first three doses of Kimmtrak.

To reduce the risk of low blood pressure linked to CRS the patient may be given fluids into a vein before receiving Kimmtrak.

Treatment can continue for as long as the patient benefits from it and does not develop unacceptable side effects.

For more information about using Kimmtrak, see the package leaflet or contact your doctor or pharmacist.

## How does Kimmtrak work?

The active substance in Kimmtrak is tebentafusp, a protein that recognises and attaches to two targets simultaneously: the proteins gp100 on the surface of uveal melanoma cancer cells and CD3 on the surface of T cells (which are part of the body's natural defences). By attaching to these proteins, tebentafusp brings the tumour cells and T cells into contact, which triggers killing of melanoma cells by T cells.

## What benefits of Kimmtrak have been shown in studies?

A study in 378 adults with advanced uveal melanoma investigated Kimmtrak and compared it with other medicines (either dacarbazine, ipilimumab or pembrolizumab). Patients given Kimmtrak survived for 21.7 months compared with 16.0 months for patients given a comparator medicine. Patients treated with Kimmtrak lived on average 3.3 months before their cancer came back, a new melanoma occurred or they died, compared with 2.9 months for patients treated with comparator medicines.

## What are the risks associated with Kimmtrak?

The most common side effects with Kimmtrak (which may affect more than 3 in 10 people) are cytokine release syndrome, rash, fever, itching, tiredness, nausea, chills, abdominal (belly) pain, oedema (swelling), hypo/hyperpigmentation (change in colouring of the skin), hypotension (low blood pressure), dry skin, headache and vomiting.

For the full list of side effects and restrictions of Kimmtrak, see the package leaflet.

## Why is Kimmtrak authorised in the EU?

There is no standard of care for patients with uveal melanoma, and therefore a high unmet medical need exists for new and effective treatments. The main study showed meaningful improvements with Kimmtrak in terms of overall survival. The side effects are considered manageable but can be serious, especially during the first 3 treatments and patients should therefore be hospitalised for their first 3 doses.

The European Medicines Agency decided that Kimmtrak's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Kimmtrak?

The company that markets Kimmtrak will provide educational materials for healthcare professionals expected to use the medicine with information on its safety, including the potential risk of CRS and how to manage the risks. Patients will also receive a guide describing the symptoms of CRS and when to seek medical attention.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kimmtrak have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Kimmtrak are continuously monitored. Suspected side effects reported with Kimmtrak are carefully evaluated and any necessary action taken to protect patients.

## Other information about Kimmtrak

Kimmtrak received a marketing authorisation valid throughout the EU on 01 April 2022.

Kimmtrak : EPAR - Medicine overview

Reference Number: EMA/128686/2022

English (EN) (121.9 KB - PDF)

**First published:** 22/04/2022

[View](/en/documents/overview/kimmtrak-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-552)

български (BG) (147.98 KB - PDF)

**First published:**

22/04/2022

[View](/bg/documents/overview/kimmtrak-epar-medicine-overview_bg.pdf)

español (ES) (121.34 KB - PDF)

**First published:**

22/04/2022

[View](/es/documents/overview/kimmtrak-epar-medicine-overview_es.pdf)

čeština (CS) (144.28 KB - PDF)

**First published:**

22/04/2022

[View](/cs/documents/overview/kimmtrak-epar-medicine-overview_cs.pdf)

dansk (DA) (119.7 KB - PDF)

**First published:**

22/04/2022

[View](/da/documents/overview/kimmtrak-epar-medicine-overview_da.pdf)

Deutsch (DE) (124.23 KB - PDF)

**First published:**

22/04/2022

[View](/de/documents/overview/kimmtrak-epar-medicine-overview_de.pdf)

eesti keel (ET) (108.15 KB - PDF)

**First published:**

22/04/2022

[View](/et/documents/overview/kimmtrak-epar-medicine-overview_et.pdf)

ελληνικά (EL) (146.9 KB - PDF)

**First published:**

22/04/2022

[View](/el/documents/overview/kimmtrak-epar-medicine-overview_el.pdf)

français (FR) (122.97 KB - PDF)

**First published:**

22/04/2022

[View](/fr/documents/overview/kimmtrak-epar-medicine-overview_fr.pdf)

hrvatski (HR) (143.76 KB - PDF)

**First published:**

22/04/2022

[View](/hr/documents/overview/kimmtrak-epar-medicine-overview_hr.pdf)

italiano (IT) (120.21 KB - PDF)

**First published:**

22/04/2022

[View](/it/documents/overview/kimmtrak-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (153.16 KB - PDF)

**First published:**

22/04/2022

[View](/lv/documents/overview/kimmtrak-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (142.35 KB - PDF)

**First published:**

22/04/2022

[View](/lt/documents/overview/kimmtrak-epar-medicine-overview_lt.pdf)

magyar (HU) (143.48 KB - PDF)

**First published:**

22/04/2022

[View](/hu/documents/overview/kimmtrak-epar-medicine-overview_hu.pdf)

Malti (MT) (146.33 KB - PDF)

**First published:**

22/04/2022

[View](/mt/documents/overview/kimmtrak-epar-medicine-overview_mt.pdf)

Nederlands (NL) (121.08 KB - PDF)

**First published:**

22/04/2022

[View](/nl/documents/overview/kimmtrak-epar-medicine-overview_nl.pdf)

polski (PL) (145.95 KB - PDF)

**First published:**

22/04/2022

[View](/pl/documents/overview/kimmtrak-epar-medicine-overview_pl.pdf)

português (PT) (122.07 KB - PDF)

**First published:**

22/04/2022

[View](/pt/documents/overview/kimmtrak-epar-medicine-overview_pt.pdf)

română (RO) (142.57 KB - PDF)

**First published:**

22/04/2022

[View](/ro/documents/overview/kimmtrak-epar-medicine-overview_ro.pdf)

slovenčina (SK) (143.04 KB - PDF)

**First published:**

22/04/2022

[View](/sk/documents/overview/kimmtrak-epar-medicine-overview_sk.pdf)

slovenščina (SL) (140.06 KB - PDF)

**First published:**

22/04/2022

[View](/sl/documents/overview/kimmtrak-epar-medicine-overview_sl.pdf)

Suomi (FI) (118.31 KB - PDF)

**First published:**

22/04/2022

[View](/fi/documents/overview/kimmtrak-epar-medicine-overview_fi.pdf)

svenska (SV) (119.88 KB - PDF)

**First published:**

22/04/2022

[View](/sv/documents/overview/kimmtrak-epar-medicine-overview_sv.pdf)

Kimmtrak : EPAR - Risk-management-plan summary

English (EN) (179.35 KB - PDF)

**First published:** 22/04/2022

[View](/en/documents/rmp-summary/kimmtrak-epar-risk-management-plan-summary_en.pdf)

## Product information

Kimmtrak : EPAR - Product information

English (EN) (590.9 KB - PDF)

**First published:** 22/04/2022

**Last updated:** 09/12/2025

[View](/en/documents/product-information/kimmtrak-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-793)

български (BG) (654.54 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/bg/documents/product-information/kimmtrak-epar-product-information_bg.pdf)

español (ES) (517.21 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/es/documents/product-information/kimmtrak-epar-product-information_es.pdf)

čeština (CS) (570.84 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/cs/documents/product-information/kimmtrak-epar-product-information_cs.pdf)

dansk (DA) (484.42 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/da/documents/product-information/kimmtrak-epar-product-information_da.pdf)

Deutsch (DE) (528.58 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/de/documents/product-information/kimmtrak-epar-product-information_de.pdf)

eesti keel (ET) (508.22 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/et/documents/product-information/kimmtrak-epar-product-information_et.pdf)

ελληνικά (EL) (628.45 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/el/documents/product-information/kimmtrak-epar-product-information_el.pdf)

français (FR) (533.69 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/fr/documents/product-information/kimmtrak-epar-product-information_fr.pdf)

hrvatski (HR) (594.64 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/hr/documents/product-information/kimmtrak-epar-product-information_hr.pdf)

íslenska (IS) (527.55 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/is/documents/product-information/kimmtrak-epar-product-information_is.pdf)

italiano (IT) (585.35 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/it/documents/product-information/kimmtrak-epar-product-information_it.pdf)

latviešu valoda (LV) (606.12 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/lv/documents/product-information/kimmtrak-epar-product-information_lv.pdf)

lietuvių kalba (LT) (612.05 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/lt/documents/product-information/kimmtrak-epar-product-information_lt.pdf)

magyar (HU) (593.21 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/hu/documents/product-information/kimmtrak-epar-product-information_hu.pdf)

Malti (MT) (679.33 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/mt/documents/product-information/kimmtrak-epar-product-information_mt.pdf)

Nederlands (NL) (516.92 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/nl/documents/product-information/kimmtrak-epar-product-information_nl.pdf)

norsk (NO) (517.21 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/no/documents/product-information/kimmtrak-epar-product-information_no.pdf)

polski (PL) (613.73 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/pl/documents/product-information/kimmtrak-epar-product-information_pl.pdf)

português (PT) (679.33 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/pt/documents/product-information/kimmtrak-epar-product-information_pt.pdf)

română (RO) (599.88 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/ro/documents/product-information/kimmtrak-epar-product-information_ro.pdf)

slovenčina (SK) (669.25 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/sk/documents/product-information/kimmtrak-epar-product-information_sk.pdf)

slovenščina (SL) (712.56 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/sl/documents/product-information/kimmtrak-epar-product-information_sl.pdf)

Suomi (FI) (506.98 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/fi/documents/product-information/kimmtrak-epar-product-information_fi.pdf)

svenska (SV) (533.89 KB - PDF)

**First published:**

22/04/2022

**Last updated:**

09/12/2025

[View](/sv/documents/product-information/kimmtrak-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000313831 08/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Kimmtrak : EPAR - All authorised presentations

English (EN) (44.26 KB - PDF)

**First published:** 22/04/2022

[View](/en/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-536)

български (BG) (61.19 KB - PDF)

**First published:**

22/04/2022

[View](/bg/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_bg.pdf)

español (ES) (46.75 KB - PDF)

**First published:**

22/04/2022

[View](/es/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_es.pdf)

čeština (CS) (62.15 KB - PDF)

**First published:**

22/04/2022

[View](/cs/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (48 KB - PDF)

**First published:**

22/04/2022

[View](/da/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (44.94 KB - PDF)

**First published:**

22/04/2022

[View](/de/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (48.49 KB - PDF)

**First published:**

22/04/2022

[View](/et/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (60.88 KB - PDF)

**First published:**

22/04/2022

[View](/el/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_el.pdf)

français (FR) (43.57 KB - PDF)

**First published:**

22/04/2022

[View](/fr/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (62.32 KB - PDF)

**First published:**

22/04/2022

[View](/hr/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (47.11 KB - PDF)

**First published:**

22/04/2022

[View](/is/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_is.pdf)

italiano (IT) (46.23 KB - PDF)

**First published:**

22/04/2022

[View](/it/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (61.96 KB - PDF)

**First published:**

22/04/2022

[View](/lv/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (60.4 KB - PDF)

**First published:**

22/04/2022

[View](/lt/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (51.93 KB - PDF)

**First published:**

22/04/2022

[View](/hu/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (64.96 KB - PDF)

**First published:**

22/04/2022

[View](/mt/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (43.39 KB - PDF)

**First published:**

22/04/2022

[View](/nl/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (47.41 KB - PDF)

**First published:**

22/04/2022

[View](/no/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_no.pdf)

polski (PL) (65.52 KB - PDF)

**First published:**

22/04/2022

[View](/pl/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_pl.pdf)

português (PT) (47.85 KB - PDF)

**First published:**

22/04/2022

[View](/pt/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_pt.pdf)

română (RO) (64.09 KB - PDF)

**First published:**

22/04/2022

[View](/ro/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (62.8 KB - PDF)

**First published:**

22/04/2022

[View](/sk/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (52.25 KB - PDF)

**First published:**

22/04/2022

[View](/sl/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (43.66 KB - PDF)

**First published:**

22/04/2022

[View](/fi/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (46.25 KB - PDF)

**First published:**

22/04/2022

[View](/sv/documents/all-authorised-presentations/kimmtrak-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Kimmtrak Active substance tebentafusp International non-proprietary name (INN) or common name tebentafusp Therapeutic area (MeSH) Uveal Neoplasms Anatomical therapeutic chemical (ATC) code L01XX75

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

## Authorisation details

EMA product number EMEA/H/C/004929

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Immunocore Ireland Limited

Unit 1 Sky Business Centres Unit 21

Opinion adopted 27/01/2022 Marketing authorisation issued 01/04/2022 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Kimmtrak : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (148.54 KB - PDF)

**First published:** 07/03/2025

**Last updated:** 09/12/2025

[View](/en/documents/procedural-steps-after/kimmtrak-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Kimmtrak : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (130.57 KB - PDF)

**First published:** 05/10/2023

**Last updated:** 07/03/2025

[View](/en/documents/procedural-steps-after/kimmtrak-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Kimmtrak-H-C-PSUSA-00010991-202401 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/430997/2024

English (EN) (108.8 KB - PDF)

**First published:** 03/12/2024

[View](/en/documents/scientific-conclusion/kimmtrak-h-c-psusa-00010991-202401-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Kimmtrak : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000068646

English (EN) (294.65 KB - PDF)

**First published:** 22/04/2022

[View](/en/documents/orphan-maintenance-report/kimmtrak-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Kimmtrak : EPAR - Public assessment report

Adopted

Reference Number: EMA/206916/2022

English (EN) (11.32 MB - PDF)

**First published:** 22/04/2022

[View](/en/documents/assessment-report/kimmtrak-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Kimmtrak

Adopted

Reference Number: EMA/CHMP/116411/2022

English (EN) (151.57 KB - PDF)

**First published:** 25/02/2022

[View](/en/documents/smop-initial/chmp-summary-opinion-kimmtrak_en.pdf)

#### News on Kimmtrak

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022) 25/02/2022

[New medicine for rare type of eye cancer](/en/news/new-medicine-rare-type-eye-cancer) 25/02/2022

#### More information on Kimmtrak

- [EU/3/21/2397 - orphan designation for treatment of uveal melanoma](/en/medicines/human/orphan-designations/eu-3-21-2397)

**This page was last updated on** 09/12/2025

## Share this page

[Back to top](#main-content)